Interested in Connecting? Please contact: Dr David Tuch CEO & Founder email@example.com
Message the company or request a 1:1 meeting here.
Lightpoint has two miniaturized robotic probes in development. The technologies incorporate recent advances in miniaturized sensors and detect cancer-targeted drugs already validated for whole-body imaging, such as SPECT/PET scans. The miniaturized probes aim to accurately identify cancer, enabling the full removal of diseased tissue, or confirm its absence, helping to preserve healthy, functional tissue. SENSEI® is our first robotic probe. Find out more in the video below.